Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:782

Genetic Technologies Limited (GTG) - Financial and Strategic SWOT Analysis Review

Genetic Technologies Limited (GTG) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Genetic Technologies Limited (GTG) is a research based life science company specializing in the field of genetics and genomics. GTG provides diagnostic products for cancer management. It offers its products and services genetic testing including cancer di
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Genetic Technologies Limited (GTG) is a research based life science company specializing in the field of genetics and genomics. GTG provides diagnostic products for cancer management. It offers its products and services genetic testing including cancer diagnostics, licensing, and research. The company offers genetic testing services for genetic testing of human, animal and plants. It offers genetic testing for parentage, disease susceptibility, individual identity, forensics and sports performance in humans and genetic testing in plant and animals for traits and disease susceptibility. Its operations are spread over the markets of Australia, Canada and Switzerland.

Genetic Technologies Limited Key Recent Developments

Feb 22, 2013: Genetic Technologies Reports H1 Fiscal 2013 Results
Dec 10, 2012: Genetic Technologies Appoints Alison Mew As CEO
Nov 28, 2012: Genetic Technologies Appoints Alison Mew As Acting CEO
Nov 27, 2012: Genetic Technologies Announces Resignation Of Paul MacLeman As CEO
Oct 15, 2012: Genetic Technologies Files Patent Infringement Suits Against Multiple Alleged Infringers In USGDPH56827FSA

This comprehensive SWOT profile of Genetic Technologies Limited provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Genetic Technologies Limited - Key Facts 5
Genetic Technologies Limited - Key Employees 6
Genetic Technologies Limited - Key Employee Biographies 7
Genetic Technologies Limited - Major Products and Services 8
Genetic Technologies Limited - History 9
Genetic Technologies Limited - Company Statement 12
Genetic Technologies Limited - Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Genetic Technologies Limited - Business Description 15
Genetic Technologies Limited - SWOT Analysis 16
SWOT Analysis - Overview 16
Genetic Technologies Limited - Strengths 16
Strength - Market Leading Position 16
Strength - Strong Intellectual Property Portfolio 16
Genetic Technologies Limited - Weaknesses 16
Weakness - Weak Operational Efficiency 16
Weakness - Patent Infringement Suits 16
Genetic Technologies Limited - Opportunities 17
Opportunity - Key Business Initiatives 17
Opportunity - Australia's Ageing Population 17
Opportunity - Market Potential: Oncology 17
Genetic Technologies Limited - Threats 18
Threat - Reliance on Proprietary Technologies 18
Threat - Increasing Competitive Pressures 18
Threat - Stringent Government Regulations 18
Genetic Technologies Limited - Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios - Capital Market Ratios 20
Financial Ratios - Annual Ratios 20
Performance Chart 22
Financial Performance 22
Financial Ratios - Interim Ratios 23
Financial Ratios - Ratio Charts 24
Section 4 – Company’s Lifesciences Financial Deals and Alliances 25
Genetic Technologies Limited, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 25
Genetic Technologies Limited, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 26
Genetic Technologies Limited, Recent Deals Summary 27
Section 5 – Company’s Recent Developments 28
Genetic Technologies Limited, Recent Developments 28
Feb 22, 2013: Genetic Technologies Reports H1 Fiscal 2013 Results 28
Dec 10, 2012: Genetic Technologies Appoints Alison Mew As CEO 32
Nov 28, 2012: Genetic Technologies Appoints Alison Mew As Acting CEO 32
Nov 27, 2012: Genetic Technologies Announces Resignation Of Paul MacLeman As CEO 32
Oct 15, 2012: Genetic Technologies Files Patent Infringement Suits Against Multiple Alleged Infringers In US 32
Aug 30, 2012: Genetic Technologies Files Patent Infringement Suit Against Reproductive Genetics Institute In US 33
Aug 27, 2012: Genetic Technologies Reports Fiscal 2012 Results 33
Feb 29, 2012: Genetic Technologies Provides Update On US And Australian Gene Patenting Litigation 33
Feb 27, 2012: Genetic Technologies Reports H1 Fiscal 2012 Results 34
Feb 21, 2012: Genetic Technologies Successfully Concludes Second Patent Infringement Suit In US 35
Section 6 – Appendix 36
Methodology 36
Ratio Definitions 36
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Genetic Technologies Limited, Key Facts 5
Genetic Technologies Limited, Key Employees 6
Genetic Technologies Limited, Key Employee Biographies 7
Genetic Technologies Limited, Major Products and Services 8
Genetic Technologies Limited, History 9
Genetic Technologies Limited, Subsidiaries 14
Genetic Technologies Limited, Key Competitors 19
Genetic Technologies Limited, Ratios based on current share price 20
Genetic Technologies Limited, Annual Ratios 20
Genetic Technologies Limited, Interim Ratios 23
Genetic Technologies Limited, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 25
Genetic Technologies Limited, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 26
Genetic Technologies Limited, Recent Deals Summary 27
Currency Codes 36
Capital Market Ratios 36
Equity Ratios 37
Profitability Ratios 37
Cost Ratios 38
Liquidity Ratios 38
Leverage Ratios 39
Efficiency Ratios 39

List of Figures
Genetic Technologies Limited, Performance Chart (2008 - 2012) 22
Genetic Technologies Limited, Ratio Charts 24
Genetic Technologies Limited, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 25
Genetic Technologies Limited, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 26




...